Atul Gawande’s announcement last week that he was stepping down as CEO of a high-profile health venture created by the leaders of Amazon, JPMorgan Chase, and Berkshire Hathaway, came after a frustrating two years marked by high turnover in key positions, potential duplication with the work of one of its founding companies, and halting progress toward its goals, a STAT examination has found.